

Supplemental Figure 1. (A) Day 20 *ex vivo* biodistribution data of ^{89}Zr -trastuzumab, in mice bearing OE19 treated with bevacizumab (5 mg/kg) on day 13, 16 and 19. The %ID/g \pm SD is shown for non-tumor tissue and tumor for ^{89}Zr -trastuzumab. (B) The day 20 *ex vivo* biodistribution tumor uptake (%ID/g) in the OE19 model correlated with the day 20 *in vivo* PET tumor uptake (%ID/g), $R^2 = 0.71$ for OE19.